ATYR Atyr Pharma Inc
Price (delayed)
$2.88
Market cap
$255.91M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.86
Enterprise value
$255.19M
atyr pharma (nasdaq: life) is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly
Highlights
The debt has contracted by 12% YoY and by 2.1% from the previous quarter
ATYR's EPS is up by 9% since the previous quarter and by 9% year-on-year
The company's equity fell by 23% YoY but it rose by 7% QoQ
Atyr Pharma's quick ratio has decreased by 19% YoY but it has increased by 2.4% from the previous quarter
The revenue fell by 33% YoY
The company's gross profit fell by 33% YoY
Key stats
What are the main financial stats of ATYR
Market
Valuations
Earnings
Shares outstanding
88.86M
Market cap
$255.91M
Enterprise value
$255.19M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.45
Price to sales (P/S)
910.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,085.91
Revenue
$235,000
Gross profit
$235,000
Operating income
-$67.91M
Net income
-$64.02M
EBIT
-$64.02M
EBITDA
-$62.48M
Free cash flow
-$69.18M
Per share
Balance sheet
Liquidity
EPS
-$0.86
EPS diluted
-$0.86
Free cash flow per share
-$0.93
Book value per share
$0.83
Revenue per share
$0
TBVPS
$1.3
Total assets
$96.83M
Total liabilities
$27M
Debt
$13.28M
Equity
$70.02M
Working capital
$66.99M
Debt to equity
0.19
Current ratio
5.48
Quick ratio
5.13
Net debt/EBITDA
0.01
Margins
Efficiency
Dividend
EBITDA margin
-26,588.5%
Gross margin
100%
Net margin
-27,243.8%
Operating margin
-28,899.6%
Return on assets
-62.8%
Return on equity
-85%
Return on invested capital
-71.6%
Return on capital employed
-78.2%
Return on sales
-27,243.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ATYR stock price
How has the Atyr Pharma stock price performed over time
Intraday
-4.64%
1 week
-17.48%
1 month
-27.18%
1 year
50.79%
YTD
-20.44%
QTD
-4.64%
Financial performance
How have Atyr Pharma's revenue and profit performed over time
Revenue
$235,000
Gross profit
$235,000
Operating income
-$67.91M
Net income
-$64.02M
Gross margin
100%
Net margin
-27,243.8%
The net margin has plunged by 91% YoY
ATYR's operating margin has dropped by 86% year-on-year
The revenue fell by 33% YoY
The company's gross profit fell by 33% YoY
Growth
What is Atyr Pharma's growth rate over time
Valuation
What is Atyr Pharma stock price valuation
P/E
N/A
P/B
3.45
P/S
910.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,085.91
ATYR's EPS is up by 9% since the previous quarter and by 9% year-on-year
ATYR's P/B is 159% above its 5-year quarterly average of 1.4 and 57% above its last 4 quarters average of 2.3
The company's equity fell by 23% YoY but it rose by 7% QoQ
ATYR's P/S is 80% above its last 4 quarters average of 530.6
The revenue fell by 33% YoY
Efficiency
How efficient is Atyr Pharma business performance
ATYR's ROS has dropped by 91% year-on-year
The return on equity has dropped by 71% year-on-year and by 7% since the previous quarter
The ROA has plunged by 61% YoY and by 6% from the previous quarter
The company's return on invested capital has shrunk by 57% YoY and by 3.6% QoQ
Dividends
What is ATYR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ATYR.
Financial health
How did Atyr Pharma financials performed over time
The total assets has contracted by 20% YoY but it has grown by 6% from the previous quarter
Atyr Pharma's quick ratio has decreased by 19% YoY but it has increased by 2.4% from the previous quarter
The debt is 81% less than the equity
The company's equity fell by 23% YoY but it rose by 7% QoQ
ATYR's debt to equity is up by 12% YoY but it is down by 10% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.